Titelbild
Bild

Topas Particle Conjugates

Topas Particle Conjugates (TPCs) are small polymer-coated superparamagnetic iron oxide particles (SPIONS) conjugated with disease-relevant peptides. They are efficiently taken up into endosomal compartments of liver sinusoidal endothelial cells (LSECs). The fast and active uptake of circulating TPCs by LSECs leads to rapid clearance of the particles from the blood stream, allows an exact dosing of the antigenic peptides targeted to the liver and avoids undesired immune reactions. TPCs provide major competitive advantages, including in vivo traceability, dose-ability, biodegradability and scalability along GMP requirements.

Topas continuously drives the further development of its TPCs, for example, through the project, “Optimizing of tolerance inducing particles (OpToPas),” funded by the European Regional Development Fund (EFRE) and the Free and Hanseatic City of Hamburg. For more details, see PDF below.

Proof-of-concept of Topas’ technology platform has been established in several mouse models; pre-clinical testing in other models is underway. TPCs are covered by solid IP with rights to future IP already secured.

Bild

Topas Particle Conjugates

Topas Particle Conjugates (TPCs) are small polymer-coated superparamagnetic iron oxide particles (SPIONS) conjugated with disease-relevant peptides. They are efficiently taken up into endosomal compartments of liver sinusoidal endothelial cells (LSECs). The fast and active uptake of circulating TPCs by LSECs leads to rapid clearance of the particles from the blood stream, allows an exact dosing of the antigenic peptides targeted to the liver and avoids undesired immune reactions. TPCs provide major competitive advantages, including in vivo traceability, dose-ability, biodegradability and scalability along GMP requirements.

Topas continuously drives the further development of its TPCs, for example, through the project, “Optimizing of tolerance inducing particles (OpToPas),” funded by the European Regional Development Fund (EFRE) and the Free and Hanseatic City of Hamburg. For more details, see PDF below.

Proof-of-concept of Topas’ technology platform has been established in several mouse models; pre-clinical testing in other models is underway. TPCs are covered by solid IP with rights to future IP already secured.